查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108304

基因組編輯市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、流程、最終用戶、解決方案和階段分類

Genome Editing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球基因組編輯市場預計將從2025年的114億美元成長到2035年的403億美元，CAGR為13.4%。該成長主要得益於基因研究的快速發展、CRISPR技術臨床應用的不斷拓展以及對先進療法投資的增加。據美國國立衛生研究院（NIH）表示，「All of Us」研究計畫已招募超過74.7萬名參與者，產生了大規模的基因組和健康資料集，為精準醫療和基因研究提供支持。基因組編輯技術在罕見疾病治療、腫瘤治療、農業和藥物研發等領域的廣泛應用，推動對先進基因編輯平台的需求。

基因組編輯市場的「類型」細分包括CRISPR、TALEN、ZFN和Meganucleases。其中，CRISPR技術憑藉其高精度、高效率、低成本以及在研究、治療開發和農業生物技術領域的廣泛應用，佔據市場主導地位。基於CRISPR的方法在基因敲除、基因校正和基因組修飾中的日益普及，加速生物技術和醫學領域的創新。 TALEN和ZFN技術繼續為需要特定標靶化能力的基因組編輯應用提供支持，而Meganucleases因其在高級基因修飾策略中的潛力而備受關注。基因編輯平台的不斷進步進一步擴展基因組工程的應用範圍。

市場區隔
類型 CRISPR、TALEN、ZFN、Meganucleases、其他
產品 試劑、耗材、設備、試劑盒、其他
服務 基因合成、細胞株建構、動物模型服務、其他
技術 基因敲除、基因敲入、鹼基編輯、先導編輯、其他
組件 軟體、硬體、其他
用途 臨床應用、農業生物技術、工業生物技術、研究、其他
過程 體內、離體、其他
最終用戶 生技公司、製藥公司、學術機構、研究機構、其他
解決方案 客製化解決方案、標準解決方案、其他
階段 藥物發現、臨床前、臨床、商業化、其他

基因組編輯市場的「應用」領域包括臨床應用、農業生物技術、工業生物技術、研究和其他領域。由於基因組編輯技術在基因治療、遺傳疾病治療和個人化醫療發展的應用日益廣泛，臨床應用領域正迅速成長。研究應用領域也佔據了相當大的佔有率，因為基因組編輯工具廣泛應用於功能基因組學、疾病建模和藥物研發。農業生物技術領域也不斷發展，基因編輯技術被應用於改良作物、提高產量和增強抗病性。工業生物技術領域也日益重要，利用基因改造微生物進行生質燃料生產、生物製造和永續工業流程開發。

區域概覽

到2025年，北美將佔據全球基因組編輯市場最大佔有率，這主要得益於其強大的生物技術和製藥產業、先進的基因組研究基礎設施以及對基因編輯技術的巨額投資。該地區匯集了許多領先的生物技術公司、學術研究機構和臨床研究組織，它們正積極開發用於治療、農業和生物醫學研究的基因組編輯應用。隨著CRISPR-Cas9、TALENs和鋅指核酸酶（ZFNs）等技術的日益普及，以及細胞和基因治療領域投資的不斷成長，市場成長加速。此外，政府的大力支持、對創新療法有利的監管流程以及廣泛的產學合作，進一步鞏固了北美在全球基因組編輯市場的領先地位。

亞太地區預計將成為基因組編輯市場成長最快的地區，這主要得益於生物技術研究的拓展、政府對基因組學和精準醫療投入的增加，以及先進基因編輯技術的日益普及。中國、日本、韓國、印度和新加坡等國家正透過國家研究舉措、擴大生物技術基礎設施和增加臨床研究活動來加強其基因組研究能力。對遺傳疾病、癌症和罕見疾病創新療法的需求不斷成長，以及基因組編輯技術在農業和畜牧業改良領域的應用日益廣泛，進一步推動了該地區的市場成長。此外，在良好的資金籌措環境和技術進步的支持下，研究機構、生物技術公司和製藥企業之間合作的加強，預計將使亞太地區在整個預測期內成為成長最快的區域市場。

主要趨勢和促進因素

CRISPR和下一代基因組編輯技術的應用範圍不斷擴大：

基因組編輯市場正呈現強勁的發展趨勢，包括以CRISPR為基礎的系統、鹼基編輯和先導編輯等先進基因組編輯技術的研發與應用。這些技術能夠更精準、有效率地進行基因修飾，應用於治療、農業和科學研究領域。製藥和生物技術公司正擴大利用基因組編輯技術開發基因療法、闡明疾病機制以及發現新的藥物標靶。遞送系統的改進、編輯精度的提高以及脫靶效應的減少，進一步提升了基因組編輯平台的潛力。此外，對功能基因體學和個人化醫療的投入不斷增加，也加速了先進基因編輯解決方案的普及應用。

拓展基因療法和精準醫療應用的發展：

基因治療和個人化醫療需求的不斷成長是基因組編輯市場的主要驅動力。遺傳性疾病、癌症和罕見疾病的日益普遍促使研究人員和企業開發基於基因修飾方法的標靶治療。基因組編輯技術能夠修飾致病突變，支持開發具有長期治療潛力的創新療法。此外，製藥公司、生技公司和研究機構加大投資，以及政府對先進療法的支持性監管措施，加速臨床開發進程。在農業、藥物研發和生物醫學研究等領域的廣泛應用也推動了市場成長。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • CRISPR
    • TALEN
    • ZFN
    • Meganucleases
    • 其他
  • 市場規模及預測：依產品分類
    • 試劑
    • 消耗品
    • 裝置
    • 成套工具
    • 其他
  • 市場規模及預測：依服務分類
    • 基因合成
    • 細胞株工程
    • 動物模特兒服務
    • 其他
  • 市場規模及預測：依技術分類
    • 基因敲除
    • 基因敲入
    • 基礎編輯
    • Prime Edit
    • 其他
  • 市場規模及預測：依應用領域分類
    • 臨床應用
    • 農業生物技術
    • 工業生物技術
    • 調查
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 生技公司
    • 製藥公司
    • 學術機構
    • 研究所
    • 其他
  • 市場規模及預測：依製程分類
    • 體內
    • 離體
    • 其他
  • 市場規模及預測：依組件分類
    • 軟體
    • 硬體
    • 其他
  • 市場規模及預測：依解決方案分類
    • 客製化解決方案
    • 標準溶液
    • 其他
  • 市場規模及預測：依階段分類
    • 發現
    • 臨床前階段
    • 臨床階段
    • 商業
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Thermo Fisher Scientific
  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Sangamo Therapeutics
  • Horizon Discovery
  • Beam Therapeutics
  • Precision BioSciences
  • Bluebird Bio
  • Cellectis
  • Caribou Biosciences
  • Inscripta
  • Mammoth Biosciences
  • Synthego
  • Pairwise
  • GenScript Biotech
  • Takara Bio
  • Origene Technologies
  • Merck KGaA
  • Lonza Group

第9章 關於我們

簡介目錄
Product Code: GIS20447

The global Genome Editing Market is projected to grow from $11.4 billion in 2025 to $40.3 billion by 2035, at a compound annual growth rate (CAGR) of 13.4%. The genome editing market is supported by the rapid growth of genetic research, increasing clinical applications of CRISPR technologies, and rising investments in advanced therapies. According to the National Institutes of Health (NIH), the All of Us Research Program has enrolled more than 747,000 participants, generating large-scale genomic and health datasets to support precision medicine and genetic research. Expanding applications of genome editing in rare disease treatment, oncology, agriculture, and drug discovery are driving demand for advanced gene-editing platforms.

The Type segment of the Genome Editing Market includes CRISPR, TALEN, ZFN, meganucleases, and others. Among these, CRISPR technology dominates the market due to its high precision, efficiency, cost-effectiveness, and broad applicability across research, therapeutic development, and agricultural biotechnology. The increasing adoption of CRISPR-based approaches for gene knockout, gene correction, and genome modification is accelerating innovation in biotechnology and medicine. TALEN and ZFN technologies continue to support genome editing applications where specific targeting capabilities are required, while meganucleases are gaining attention for their potential in advanced gene modification strategies. Ongoing advancements in gene editing platforms are further expanding the scope of genome engineering applications.

Market Segmentation
TypeCRISPR, TALEN, ZFN, Meganucleases, Others
ProductReagents, Consumables, Instruments, Kits, Others
ServicesGene Synthesis, Cell Line Engineering, Animal Model Services, Others
TechnologyGene Knockout, Gene Knock-In, Base Editing, Prime Editing, Others
ComponentSoftware, Hardware, Others
ApplicationClinical Applications, Agricultural Biotechnology, Industrial Biotechnology, Research, Others
ProcessIn Vivo, Ex Vivo, Others
End UserBiotechnology Companies, Pharmaceutical Companies, Academic Institutions, Research Laboratories, Others
SolutionsCustom Solutions, Standard Solutions, Others
StageDiscovery, Preclinical, Clinical, Commercial, Others

The Application segment of the Genome Editing Market includes clinical applications, agricultural biotechnology, industrial biotechnology, research, and others. Clinical applications represent a rapidly growing segment due to increasing adoption of genome editing in gene therapies, treatment of genetic disorders, and development of personalized medicines. Research applications hold a significant share owing to extensive use of genome editing tools in functional genomics, disease modeling, and drug discovery studies. Agricultural biotechnology is expanding with the application of gene editing for crop improvement, enhanced yield, and disease resistance. Industrial biotechnology is also gaining importance through the use of engineered microorganisms for biofuel production, biomanufacturing, and sustainable industrial processes.

Geographical Overview

North America accounted for the largest share of the global genome editing market in 2025, driven by its strong biotechnology and pharmaceutical sectors, advanced genomics research infrastructure, and significant investments in gene editing technologies. The region is home to leading biotechnology companies, academic research institutions, and clinical research organizations actively developing genome editing applications for therapeutics, agriculture, and biomedical research. Increasing adoption of technologies such as CRISPR-Cas9, TALENs, and zinc finger nucleases (ZFNs), coupled with growing investments in cell and gene therapy, has accelerated market growth. Furthermore, supportive government funding, favorable regulatory pathways for innovative therapies, and extensive collaborations between industry and academia continue to reinforce North America's leadership in the global genome editing market.

Asia Pacific is expected to witness the highest growth in the genome editing market owing to expanding biotechnology research, increasing government investments in genomics and precision medicine, and growing adoption of advanced gene editing technologies. Countries such as China, Japan, South Korea, India, and Singapore are strengthening their genomic research capabilities through national research initiatives, expanding biotechnology infrastructure, and increasing clinical research activities. Rising demand for innovative treatments for genetic disorders, cancer, and rare diseases, along with growing applications of genome editing in agriculture and livestock improvement, is further driving regional market growth. Moreover, increasing collaborations between research institutions, biotechnology companies, and pharmaceutical manufacturers, supported by favorable funding and technological advancements, are expected to position Asia Pacific as the fastest-growing regional market throughout the forecast period.

Key Trends and Drivers

Expanding Applications of CRISPR and Next-Generation Genome Editing Technologies:

The Genome Editing Market is witnessing a strong trend toward the development and adoption of advanced genome editing technologies, including CRISPR-based systems, base editing, and prime editing. These technologies are enabling more precise and efficient genetic modifications across therapeutic, agricultural, and research applications. Pharmaceutical and biotechnology companies are increasingly leveraging genome editing for developing gene therapies, studying disease mechanisms, and discovering novel drug targets. Improvements in delivery systems, editing accuracy, and off-target effect reduction are further enhancing the potential of genome editing platforms. Additionally, growing investments in functional genomics and personalized medicine are accelerating the adoption of advanced gene-editing solutions.

Rising Development of Gene Therapies and Precision Medicine Applications:

The increasing demand for gene therapies and personalized medicine is a major driver of the Genome Editing Market. The growing prevalence of genetic disorders, cancer, and rare diseases is encouraging researchers and companies to develop targeted treatments based on genetic modification approaches. Genome editing technologies enable correction of disease-causing mutations and support the development of innovative therapies with long-term therapeutic potential. Furthermore, increasing investments from pharmaceutical companies, biotechnology firms, and research institutions, along with supportive regulatory initiatives for advanced therapies, are accelerating clinical development programs. Expanding applications in agriculture, drug discovery, and biomedical research are also contributing to market growth.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 CRISPR
    • 4.1.2 TALEN
    • 4.1.3 ZFN
    • 4.1.4 Meganucleases
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Reagents
    • 4.2.2 Consumables
    • 4.2.3 Instruments
    • 4.2.4 Kits
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Gene Synthesis
    • 4.3.2 Cell Line Engineering
    • 4.3.3 Animal Model Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Knockout
    • 4.4.2 Gene Knock-In
    • 4.4.3 Base Editing
    • 4.4.4 Prime Editing
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Clinical Applications
    • 4.5.2 Agricultural Biotechnology
    • 4.5.3 Industrial Biotechnology
    • 4.5.4 Research
    • 4.5.5 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Academic Institutions
    • 4.6.4 Research Laboratories
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 In Vivo
    • 4.7.2 Ex Vivo
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Software
    • 4.8.2 Hardware
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Custom Solutions
    • 4.9.2 Standard Solutions
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Discovery
    • 4.10.2 Preclinical
    • 4.10.3 Clinical
    • 4.10.4 Commercial
    • 4.10.5 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Thermo Fisher Scientific
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 CRISPR Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Editas Medicine
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Intellia Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Sangamo Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Horizon Discovery
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Beam Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Precision BioSciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Bluebird Bio
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cellectis
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Caribou Biosciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Inscripta
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Mammoth Biosciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Synthego
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pairwise
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 GenScript Biotech
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Takara Bio
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Origene Technologies
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Merck KGaA
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Lonza Group
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us